In vivo antitumor activity of ilmofosine.
Ilmofosine is a cytostatic/cytotoxic thioether phospholipid derivative. The in vivo anti-tumour activity of this compound was investigated in a methylcholanthrene (MethA)-induced fibrosarcoma and in the 3Lewis-lung carcinoma systems, respectively. Ilmofosine showed antineoplastic and antimetastatic properties at oral doses ranging from 0.625 to 40 mg/kg/day. Combination of Ilmofosine (p.o.) together with either cyclophosphamide (p.o.) or cis-DDP (i.v.) resulted in synergistic effects in vivo. These results demonstrate the in vivo antitumour activity of Ilmofosine in two tumour systems. The data indicate that direct cytostatic/cytotoxic effects of Ilmofosine are mainly responsible for its antitumour activity in vivo and which are increased by other cytotoxics.
Herrmann
D B
DB
Boehringer Mannheim GmbH, Department of Immunopharmacology, F.R.G.
Pahlke
W
W
Opitz
H G
HG
Bicker
U
U
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D005260:Female; D005354:Fibrosarcoma / Q000139:chemically induced / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D008748:Methylcholanthrene; D051379:Mice; D008810:Mice, Inbred C57BL; D008815:Mice, Inbred Strains; D009368:Neoplasm Transplantation; D010742:Phospholipid Ethers / Q000008:administration & dosage / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D010742:Phospholipid Ethers; D008748:Methylcholanthrene; C043297:ilmofosine; D003520:Cyclophosphamide; D002945:Cisplatin